Pfizer (PFE) PT Set at $48.00 by Independent Research

Independent Research set a $48.00 price target on Pfizer (NYSE:PFE) in a research report report published on Thursday. The firm currently has a neutral rating on the biopharmaceutical company’s stock.

PFE has been the subject of several other reports. Goldman Sachs Group restated a neutral rating and issued a $45.00 target price on shares of Pfizer in a research note on Tuesday, August 28th. Cantor Fitzgerald assumed coverage on Pfizer in a research note on Thursday, June 7th. They issued an overweight rating and a $45.00 target price for the company. Credit Suisse Group raised their target price on Pfizer from $39.00 to $40.00 and gave the company a neutral rating in a research note on Wednesday, August 1st. Barclays restated a neutral rating and issued a $40.00 target price on shares of Pfizer in a research note on Wednesday, September 26th. Finally, Morgan Stanley set a $45.00 target price on Pfizer and gave the company a buy rating in a research note on Thursday, September 6th. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating and nine have issued a buy rating to the company’s stock. The company currently has an average rating of Hold and a consensus price target of $42.40.

Shares of PFE opened at $44.91 on Thursday. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.16 and a quick ratio of 0.91. The stock has a market capitalization of $262.34 billion, a PE ratio of 16.95, a PEG ratio of 2.23 and a beta of 0.96. Pfizer has a one year low of $33.20 and a one year high of $45.00.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, July 31st. The biopharmaceutical company reported $0.81 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.07. The company had revenue of $13.47 billion during the quarter, compared to the consensus estimate of $13.30 billion. Pfizer had a return on equity of 25.35% and a net margin of 42.35%. The firm’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same period last year, the business posted $0.67 EPS. On average, sell-side analysts forecast that Pfizer will post 2.99 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Monday, December 3rd. Shareholders of record on Friday, November 9th will be paid a dividend of $0.34 per share. The ex-dividend date of this dividend is Thursday, November 8th. This represents a $1.36 dividend on an annualized basis and a yield of 3.03%. Pfizer’s dividend payout ratio (DPR) is currently 51.32%.

In other Pfizer news, insider Laurie J. Olson sold 10,214 shares of Pfizer stock in a transaction that occurred on Monday, August 13th. The shares were sold at an average price of $41.00, for a total transaction of $418,774.00. Following the transaction, the insider now owns 72,672 shares of the company’s stock, valued at approximately $2,979,552. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Alexander R. Mackenzie sold 25,642 shares of Pfizer stock in a transaction that occurred on Friday, August 3rd. The stock was sold at an average price of $39.51, for a total transaction of $1,013,115.42. Following the transaction, the insider now directly owns 127,954 shares in the company, valued at approximately $5,055,462.54. The disclosure for this sale can be found here. Insiders have sold a total of 761,230 shares of company stock valued at $29,054,690 in the last quarter. Company insiders own 0.06% of the company’s stock.

Several institutional investors have recently bought and sold shares of PFE. Ballew Advisors Inc bought a new stake in shares of Pfizer in the 1st quarter worth approximately $102,000. Woodard & Co. Asset Management Group Inc. ADV bought a new stake in shares of Pfizer in the 4th quarter worth approximately $118,000. Fort L.P. bought a new stake in shares of Pfizer in the 2nd quarter worth approximately $121,000. W.G. Shaheen & Associates DBA Whitney & Co bought a new stake in shares of Pfizer in the 1st quarter worth approximately $132,000. Finally, Bray Capital Advisors bought a new stake in shares of Pfizer in the 1st quarter worth approximately $139,000. 68.95% of the stock is currently owned by hedge funds and other institutional investors.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Featured Article: Stock Symbol

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply